Immune system 'double agent' could be new ally in cancer fight

March 16, 2018, St. Jude Children's Research Hospital
Immune system 'double agent' could be new ally in cancer fight
First author R.K. Subbarao Malireddi, Ph.D., pictured with Thirumala-Devi Kanneganti, Ph.D., a member of the St. Jude Children’s Research Hospital Department of Immunology. Credit: St. Jude Children's Research Hospital

St. Jude Children's Research Hospital scientists have discovered that an enzyme called TAK1 functions like a "double agent" in the innate immune response, serving as an unexpected regulator of inflammation and cell death. The findings highlight TAK1 inhibition as a potential cancer treatment.

TAK1 is a kinase known to promote inflammation. But Thirumala-Devi Kanneganti, Ph.D., a member of the St. Jude Children's Research Hospital Department of Immunology, and her colleagues showed that TAK1 can suppress inflammation as well. The research appeared online earlier this month in the Journal of Experimental Medicine.

Working in mouse immune called macrophages, the researchers demonstrated that TAK1 plays a pivotal role in restricting inflammation and by blocking spontaneous activation of the NLRP3 . The NLRP3 inflammasome is a protein complex that, when activated, helps the innate immune system recognize and mount a rapid defense against bacteria, viruses and other threats. But elevated activation of NLRP3 is also associated with human disease, including myeloproliferative and inflammatory disorders.

NLRP3 has been the focus of more than 3,500 scientific publications since Kanneganti discovered its function more than 10 years ago. "Despite ongoing research and the central role of NLRP3 in inflammation, infection and immunity, the precise regulatory mechanism governing activation of NLRP3 and its related cell-death pathways was not clearly understood," said Kanneganti, the study's corresponding author. "These findings show that TAK1 is a central regulator of NLRP3 inflammasome homeostasis.

"The findings add to evidence that inhibitors of TAK1 and other molecules in the pathway may have a role in cancer therapy by promoting tumor cell death," she said.

NLRP3 activation normally requires two signals. TAK1's role in the process came to light when co-first author Prajwal Gurung, Ph.D., then a postdoctoral fellow in Kanneganti's laboratory and now at the University of Iowa Carver College of Medicine, made a surprising observation.

Without TAK1, macrophages derived from mouse bone marrow died spontaneously in the laboratory even in the absence of the signals normally required to activate NLRP3. Macrophages with TAK1 did not. But the normal (wild type) macrophages did die when treated with a TAK1 inhibitor.

"Such spontaneous cell death was unexpected," added first author R.K. Subbarao Malireddi, Ph.D., a scientist in Kanneganti's laboratory. "We went on to show that macrophages lacking TAK1 died due to spontaneous activation of signaling pathways that promoted NLRP3 inflammasome activation and cell death."

The consequences of TAK1 deficiency included a biochemical cascade that activated the enzymes RIPK1 and caspase-1. Caspase-1 prompts production of proteins like IL-18 and IL-1β that promote inflammation and cell death via the inflammatory cell-death pathway (pyroptosis). Researchers also detailed other molecules that drove the process in the absence of TAK1, including tumor necrosis factor.

NLRP3 is one of the five major inflammasomes involved in the . However, Kanneganti and colleagues reported that only the NLRP3 inflammasome is spontaneously activated in macrophages in the absence of TAK1.

This study also adds to the evidence that TAK1 inhibitors may have a role in cancer immune therapy. Compounds that inhibit TAK1 stopped cell proliferation in mice, underscoring their potential in cancer treatment. Kanneganti said that is not surprising since their findings showed that, along with pyroptosis, TAK1 also inhibits apoptotic and necroptotic cell-death pathways.

"This research connects TAK1, the NLRP3 inflammasome and RIPK1, apparently for the first time, advancing our understanding of a number of key pathways," Kanneganti said.

Explore further: From black hat to white hat: Findings tip assumptions about TAK1 in muscle growth

More information: R.K. Subbarao Malireddi et al. TAK1 restricts spontaneous NLRP3 activation and cell death to control myeloid proliferation, The Journal of Experimental Medicine (2018). DOI: 10.1084/jem.20171922

Related Stories

From black hat to white hat: Findings tip assumptions about TAK1 in muscle growth

February 8, 2018
Among researchers exploring the mechanisms of muscle growth and health, there have been certain conceptions about the role of the signaling protein, transforming growth factor-ß-activated kinase 1 (TAK1). Convention was ...

Loss of inflammatory signaling molecule protects mice against diet-induced obesity

May 19, 2016
Obesity and subsequent complications are increasing in frequency worldwide. The accumulation of adipose tissue is associated with increased inflammation, and it has been proposed that modification of proinflammatory responses ...

Research confirms that melatonin could prevent sepsis, top cause of death in hospital ICUs

January 26, 2016
Sepsis is a serious disease that takes place when the body has an excessive immune response to a bacterial infection. It's the leading cause of death in hospitaL intensive care units (ICUs), and there's no specific treatment ...

Researchers uncover key role for microRNA in inflammatory bowel disease

May 9, 2017
An international team of researchers has discovered that a microRNA produced by certain white blood cells can prevent excessive inflammation in the intestine. The study, "Myeloid-derived miR-223 regulates intestinal inflammation ...

Scientists Uncover Protective Mechanism Against Liver Cancer

December 14, 2009
(PhysOrg.com) -- A team of scientists from the UC San Diego School of Medicine and Osaka University in Japan have identified a protein switch that helps prevent liver damage, including inflammation, fibrosis and cancer. The ...

Study details machinery of immune protection against inflammatory diseases like colitis

March 18, 2010
Scientists report a protein made by a gene already associated with a handful of human inflammatory immune diseases plays a pivotal role in protecting the intestinal tract from colitis.

Recommended for you

Major breakthrough in quest for cancer vaccine

December 6, 2018
The idea of a cancer vaccine is something researchers have been working on for over 50 years, but until recently they were never able to prove exactly how such a vaccine would work.

Newly identified T cells could play a role in cancer and other diseases

December 6, 2018
Researchers from the UCLA Jonsson Comprehensive Cancer Center and the La Jolla Institute for Immunology have identified a new type of T cell called a phospholipid-reactive T cell that is able to recognize phospholipids, the ...

Classifying brain microglia: Which are good and which are bad?

December 6, 2018
Microglia are known to be important to brain function. The immune cells have been found to protect the brain from injury and infection and are critical during brain development, helping circuits wire properly. They also seem ...

Memory B cells in the lung may be important for more effective influenza vaccinations

December 5, 2018
Seasonal influenza vaccines are typically less than 50 percent effective, according to Centers for Disease Control and Prevention studies. Research at the University of Alabama at Birmingham, published this week in Nature ...

Tuberculosis survives by using host system against itself, study finds

December 5, 2018
In a new study published in the Journal of Experimental Medicine, scientists at the University of Notre Dame have discovered that the pathogen Mycobacterium tuberculosis (MTB) releases RNA into infected cells. This RNA stimulates ...

RSV study reveals age when infants are most vulnerable to asthma

December 5, 2018
New research suggests a maternal vaccination against RSV should be augmented with active immunisation in a child's first two years to reduce the onset of asthma.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.